GoodRx Holdings, Inc.
GDRX Healthcare Health Information Services
GoodRx Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $796.9 million, up 0.57% from fiscal 2024. In the quarter to June 2026, revenue fell 1.31%, EPS fell 25.0%, free cash flow grew 112.5% and total debt was flat, each against the same quarter a year earlier.
Follow GDRX
GoodRx Holdings, Inc. (GDRX) P/E ratio
As of 16 October 2026, GoodRx Holdings, Inc. (GDRX) trades at a P/E ratio of 62.7×. Over the past ten years it has ranged from 0.0× (December 2024) to 843× (October 2020); the current reading is higher than 81% of that period. That is above the Health Information Services industry median of 39.8× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 30.0× | (69.37%) |
| FY2024 | 98.1× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 139× | 0.00% |
| FY2018 | 139× | 0.00% |
| FY2017 | 139× | 0.00% |
| FY2016 | 139× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 53.7× | 74.35% |
| Mar 2026 | 30.8× | 2.57% |
| Dec 2025 | 30.0× | (33.80%) |
| Sep 2025 | 45.4× | (8.86%) |
| 24 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MDRX Veradigm Inc. compare | n/m |
| TDOC Teladoc Health, Inc. compare | n/m |
| SDGR Schrodinger, Inc. compare | n/m |
| CERT Certara, Inc. compare | n/m |
| OMCL Omnicell, Inc. compare | 41.6× |
| HSTM HealthStream, Inc. compare | 46.0× |
| GDRX GoodRx Holdings, Inc. | 62.7× |
| PHR Phreesia, Inc. compare | 64.4× |
| OMDA Omada Health, Inc. compare | 252× |
| Health Information Services industry median | 39.8× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)